BIOCRYST PHARMACEUTICALS, INC.: 10-Q filed 2024-08-06
What BIOCRYST PHARMACEUTICALS, INC. reported in its quarterly report filed 2024-08-06 (fiscal Q2 2024): 39 published measures, 108 facts as tagged in accession 0001628280-24-035170.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2024-08-06
- Fiscal period
- fiscal Q2 2024
- Accession
- 0001628280-24-035170 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOCRYST PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 472,419,000 | USD | |
| At 2023-12-31 | 516,960,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | -475,606,000 | USD | |
| At 2024-03-31 | -476,167,000 | USD | |
| At 2023-12-31 | -455,528,000 | USD | |
| At 2023-06-30 | -388,713,000 | USD | |
| At 2023-03-31 | -328,287,000 | USD | |
| At 2022-12-31 | -294,597,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 78,410,000 | USD | |
| At 2023-12-31 | 110,643,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -12,674,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -48,053,000 | USD | 182 |
| 2024-01-01 to 2024-03-31 | -35,379,000 | USD | 91 |
| 2023-04-01 to 2023-06-30 | -75,326,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -128,659,000 | USD | 181 |
| 2023-01-01 to 2023-03-31 | -53,333,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | -55,052,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -66,326,000 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | -3,014,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 34,433,000 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 26,307,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -126,144,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | -1,729,212,000 | USD | |
| At 2023-12-31 | -1,681,159,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 206,425,000 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 206,244,000 | shares | 182 |
| 2023-04-01 to 2023-06-30 | 189,118,000 | shares | 91 |
| 2023-01-01 to 2023-06-30 | 188,815,000 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 206,425,000 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 206,244,000 | shares | 182 |
| 2023-04-01 to 2023-06-30 | 189,118,000 | shares | 91 |
| 2023-01-01 to 2023-06-30 | 188,815,000 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -0.06 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -0.23 | USD/shares | 182 |
| 2023-04-01 to 2023-06-30 | -0.4 | USD/shares | 91 |
| 2023-01-01 to 2023-06-30 | -0.68 | USD/shares | 181 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -0.06 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -0.23 | USD/shares | 182 |
| 2023-04-01 to 2023-06-30 | -0.4 | USD/shares | 91 |
| 2023-01-01 to 2023-06-30 | -0.68 | USD/shares | 181 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 172,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 537,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 740,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 1,411,000 | USD | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 7,663,000 | USD | |
| At 2023-12-31 | 7,910,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 26,825,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 26,848,000 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 8,761,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -5,727,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -20,703,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -49,118,000 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 363,457,000 | USD | |
| At 2023-12-31 | 495,966,000 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 24,733,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 49,239,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 28,915,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 56,311,000 | USD | 181 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 129,065,000 | USD | |
| At 2023-12-31 | 149,988,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 7,786,000 | USD | |
| At 2023-12-31 | 20,893,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 68,759,000 | USD | |
| At 2023-12-31 | 56,950,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 4,450,000 | USD | |
| At 2023-12-31 | 28,683,000 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 61,214,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 120,578,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 50,997,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 98,864,000 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 37,623,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 84,116,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 51,247,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 99,635,000 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 206,629,000 | shares | |
| At 2023-12-31 | 205,771,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 1,250,983,000 | USD | |
| At 2023-12-31 | 1,222,236,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 557,000 | USD | |
| At 2023-12-31 | 1,337,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 8,535,000 | USD | |
| At 2023-12-31 | 8,682,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 9,388,000 | USD | |
| At 2023-12-31 | 9,448,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 12,457,000 | USD | |
| At 2023-12-31 | 13,084,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 89,598,000 | USD | |
| At 2023-12-31 | 102,882,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 16,426,000 | USD | |
| At 2023-12-31 | 19,542,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -12,502,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -47,516,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -74,586,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -127,248,000 | USD | 181 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -12,888,000 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -48,833,000 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -75,221,000 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -127,995,000 | USD | 181 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 626,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 812,000 | USD | 181 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 10,041,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 12,300,000 | USD | 181 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 1,084,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 874,000 | USD | 181 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 481,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -1,029,000 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | -57,103,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -27,414,000 | USD | 181 |
Inspect the source
- Entity
- BIOCRYST PHARMACEUTICALS, INC. / CIK 0000882796
- Captured
- 2026-09-20T05:02:04.268Z
- SEC response SHA-256
64fec42b290a9661564adfbe60f6de7df3ea9fe9bff3ac7d73b79819a05c52a5
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000882796.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))